Bayer stops trial of drug it hopes will be a blockbuster

Dec 05, 2018

Bayer has halted testing for vilaprisan, a new medication developed to treat uterine fibroids. The company said that it’s concerned about the risk of side effects uncovered in toxicology data. 

“We recently observed safety signals in pre-clinical toxicological studies in rodents investigating long term safety of vilaprisan — a drug candidate we develop for the treatment of uterine fibroids and endometriosis,” Bayer stated. “Although these are preliminary pre-clinical findings that have not been observed in other vilaprisan studies we decided as a precautionary measure to pause recruitment in the ongoing clinical studies with vilaprisan until a thorough analysis of the findings has been achieved.”

Bayer had predicted that peak annual sales for vilaprisan could reach $1.1 billion. 

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments